PRIMALung (EORTC 1901-LCG)
Research type
Research Study
Full title
PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in small-cell Lung cancer patients (PRIMALung study)
IRAS ID
306415
Contact name
Corinne Faivre-Finn
Contact email
Sponsor organisation
European Organisation for the Research and Treatment of Cancer (EORTC)
Clinicaltrials.gov Identifier
Duration of Study in the UK
8 years, 8 months, 31 days
Research summary
This study is for adults who have Small Cell Lung Cancer (SCLC) who have received treatment. It is quite common for this type of cancer to spread (metastasise) to the brain, so prophylactic cerebral irradiation (PCI) treatment may be offered to reduce the risk of this spread. However, PCI has its own side effects so the study will look at the option of using active surveillance (using brain MRI scans) to monitor the disease.
The study is looking at whether regular monitoring of the brain with MRI scans, compared to radiation treatment will be no worse for patients’ survival, but will reduce the side effects that the patient experiences.
This study will take place in NHS sites in the UK as part of a wider international study. The study is sponsored and coordinated by the EORTC (European Organisation for Research and Treatment of Cancer), a non-profit organisation based in Brussels.
REC name
East Midlands - Derby Research Ethics Committee
REC reference
22/EM/0120
Date of REC Opinion
4 Jul 2022
REC opinion
Further Information Favourable Opinion